Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pra-Ornsuda Sukrakanchana has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oral Fluid Concentrations of Tenofovir and Emtricitabine for Monitoring HIV Antiretroviral Adherence: Findings From a Randomized Trial with Directly Observed Therapy (TARGET Study)

    by Xin Niu, Tiancheng E Edwards, Jeannette A Dienhart, Richard E Haaland, Oraphan Siriprakaisil, Pra-Ornsuda Sukrakanchana, Tim R Cressey, Paul K Drain

    Background: Early identification of non-adherence to daily antiretroviral therapies may facilitate targeted transition to long-acting HIV regimens for individuals most likely to benefit. This study evaluated the feasibility of detecting emtricitabine (FTC) and tenofovir (TFV) in oral fluids to monitor daily oral pre-exposure prophylaxis (PrEP) adherence. Methods: We collected 241 oral fluids from 22 HIV-negative adults randomized to 2, 4, or 7 doses/week of oral PrEP with FTC/TDF for directly observed therapy. Generalized Estimating Equations were used to examine the associations between FTC/TFV detectability and three dimensions of PrEP adherence: dosing recency, cumulative dosing time, and dosing frequency. We also assessed the diagnostic accuracy of FTC levels in oral fluids for predicting daily oral PrEP non-adherence (time since the last dose >24 hours). Results: Among 165 oral fluids with a time since the last dose within 48 hours, 9.0% had detectable TFV, and 53.3% had detectable FTC. Compared with oral fluids collected within 24 hours since the last dose, those collected between 24 and 48 hours since the last dose had significantly lower odds of having detectable FTC (odds ratio: 0.21, 95% confidence interval [CI]: 0.11–0.38). An FTC threshold of <7.5 ng/mL achieved a sensitivity of 90% (95% CI: 84%–94%) and a specificity of 65% (95% CI: 57%–74%) for identifying recent PrEP non-adherence. Conclusions: FTC can be detected in oral fluids and may be a promising pharmacologic marker for identifying recent PrEP non-adherence as early as one dose missed. TFV had lower concentrations in oral fluids, and is not suitable for adherence monitoring. Clinical Trials Registration. NCT0301260.


  • Open Access

    Stigma and Discrimination among Adolescents Living with Perinatal HIV in Thailand: Reports from Their Caregivers

    by Audrey Geoffroy, Wasna Sirirungsi, Parinya Jongpaijitsakul, Wanna Chamjamrat, Chutima Ruklao, Manoosin Kongka, Usa Sukhaphan, Somporn Sathan, Sriphan Thina, Tassawan Khayanchoomnoom, et al.

    In Thailand, thousands of children living with perinatal HIV have been exposed to HIV-related stigma/discrimination but its frequency and expressions have been little studied. Our objective was to assess stigma/discrimination prevalence, associated risks factors and its expressions among adolescents. All caregivers of adolescents aged 12-19 years living with perinatal HIV and receiving antiretrovirals in 20 hospitals throughout Thailand were invited to complete a face-to-face questionnaire on their adolescent’s life and medical history. Of the 572 adolescents living in family settings, 464 had their HIV-status known in the community. The overall stigma/discrimination prevalence was 46%. Factors associated included living in the north-east region (OR: 2.80, 95%CI: 1.19-4.96), having a low intellectual ability (OR:2.68, 95%CI: 1.45-5.16), a lower Body Mass Index (BMI) (OR BMI > 18.5: 0.61, 95%CI: 0.37-0.98), conflicts with caregivers (OR: 1.86, 95%CI: 1.26-2.76) and caregivers being members of a support group (OR: 2.34, 95%CI: 1.58-3.48). Expressions of stigma/discrimination included bullying, social isolation, behavioral discrimination and public disclosure. The prevalence of stigma/discrimination among adolescents living with perinatal HIV is high. Despite existing policies, stigma eradication remains necessary to normalize their life as they grow into adulthood.


  • Open Access

    Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand

    by Nicolas Salvadori, Gonzague Jourdain, Rungroj Krittayaphong, Taweegrit Siripongboonsitti, Subsai Kongsaengdao, Kriangsak Atipornwanich, Parichart Sakulkonkij, Nasikarn Angkasekwinai, Rujipas Sirijatuphat, Sarunyou Chusri, et al.


  • Open Access

    Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital Setting

    by Amy Riddell, Aislinn Cook, Nathalie Khavessian, Sally Ellis, Davide Bilardi, Erika Correia, Tomislav Kostyanev, Alessandra Nardone, Neal Russell, Tuba Vilken, et al.

    Neonatal sepsis is a significant cause of mortality and morbidity in low- and middle-income countries. To deliver high-quality data studies and inform future trials, it is crucial to understand the challenges encountered when managing global multi-centre research studies and to identify solutions that can feasibly be implemented in these settings. This paper provides an overview of the complexities faced by diverse research teams in different countries and regions, together with actions implemented to achieve pragmatic study management of a large multi-centre observational study of neonatal sepsis. We discuss specific considerations for enrolling sites with different approval processes and varied research experience, structures, and training. Implementing a flexible recruitment strategy and providing ongoing training were necessary to overcome these challenges. We emphasize the attention that must be given to designing the database and monitoring plans. Extensive data collection tools, complex databases, tight timelines, and stringent monitoring arrangements can be problematic and might put the study at risk. Finally, we discuss the complexities added when collecting and shipping isolates and the importance of having a robust central management team and interdisciplinary collaborators able to adapt easily and make swift decisions to deliver the study on time and to target. With pragmatic approaches, appropriate training, and good communication, these challenges can be overcome to deliver high-quality data from a complex study in challenging settings through a collaborative research network.


  • Open Access

    A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study

    by Tim R. Cressey, Oraphan Siriprakaisil, Virat Klinbuayaem, Justice Quame-Amaglo, Rachel W. Kubiak, Pra-Ornsuda Sukrakanchana, Kanchana Than-In-At, Jared Baeten, Wasna Sirirungsi, Ratchada Cressey, et al.

    Tenofovir disoproxil fumarate (TDF) is key component of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for HIV, but existing tools to monitor drug adherence are often inaccurate. Detection of tenofovir (TFV) in accessible biological samples, such as fingerprick blood, urine or oral fluid samples could be a novel objective measure of recent TDF adherence. To measure TFV concentrations associated with different levels of TDF adherence, we designed a randomized clinical trial to assess the blood, urine and oral fluid concentrations of TFV in adults with perfect, moderate and low drug adherence. A randomized, open-label, clinical pharmacokinetic study of tenofovir in healthy adult volunteers without HIV or Hepatitis B infection in Thailand. Consenting, eligible participants are randomized (1:1:1) among three groups to receive a controlled number of TDF (300 mg) doses in a combination pill with emtricitabine (FTC, 200 mg) for six weeks. Participants in Group 1 receive a single TDF/FTC tablet once daily (Perfect adherence); Group 2 receive a single TDF/FTC tablet 4 times/week (Moderate adherence); and Group 3 receive a single TDF/FTC tablet 2 times/week (Low adherence). Blood, plasma, urine and oral fluid samples are collected for drug measurement during three study phases: (i) initial 6-week treatment phase; (ii) intensive 24-h blood sampling phase after 6 weeks; (iii) 4-week washout phase. Thirty adults with evaluable pharmacokinetic samples (10 per group) will be enrolled [based on ensuring 25% precision in pharmacokinetic parameter estimates]. Pre-dose drug concentrations during the treatment phase will be descriptive and comparisons between groups performed using a Kruskal-Wallis test. A non-compartmental pharmacokinetic analysis will be performed on the intensive sampling data at Week 7 and the time course of TFV washout in the difference biological matrices will be reported based on the detected concentrations following drug cessation. The results of this randomized trial will define the target concentration thresholds of TFV in blood, urine and oral fluid that can distinguish between different levels of TDF adherence. Such adherence ‘benchmarks’ can be applied to real-time drug testing and novel point-of-care tests to identify individuals with poor PrEP or ART adherence. ClinicalTrials.gov Identifier NCT03012607 .